Article
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Scientific reports - 27 Aug 2021
Corné Julien, Le Du Fanny, Quillien Véronique, Godey Florence, Robert Lucie, Bourien Héloïse, Brunot Angélique, Crouzet Laurence, Perrin Christophe, Lefeuvre-Plesse Claudia, Diéras Véronique, De la Motte Rouge Thibault
Abstract excerpt
With the approval of new therapies targeting the PI3K pathway, the detection of PIK3CA mutations has become a key factor in treatment management for HR+/HER2- metastatic breast cancer (MBC). We developed multiplex digital PCR (dPCR) assays to detect and quantify PIK3CA mutations. A first screening assay allows the detection of 21 mutations, with a drop-off system targeting the 542-546 hotspot mutations combined...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.